Department of General Surgery, Altinbas University Faculty of Medicine Medical Park Bahcelievler Hospital, Istanbul, Turkey.
Eur Rev Med Pharmacol Sci. 2020 Oct;24(20):10512-10517. doi: 10.26355/eurrev_202010_23403.
To evaluate the diagnostic and prognostic utility of nucleosome assembly protein 1-like 1 (NAP1L1) in colon cancer patients.
A total of 95 patients with colon cancer [mean (SD) age: 61.0 (1.7) years, 58.9% were males] and 50 healthy individuals [mean (SD) age: 61.0 (2.3) years, 52.0% were males] were included in this prospective multicenter study. Data on patient demographics (age, gender) and serum NAP1L1 levels were recorded in both control and colon cancer groups. In colon cancer patients, serum NAP1L1 levels were further analyzed with respect to TNM stages and tumor size.
Serum NAP1L1 levels were significantly higher in colon cancer patients as compared with control subjects [median (min-max) 14(12-16) vs. 2(1-2) ng/mL, p<0.001]. In colon cancer patients, serum NAP1L1 levels were significantly higher for tumor size of >4 cm vs. <4 cm [15(12-16) vs. 12(12-14) ng/mL), p<0.001] and for M1 vs. M0 stage [15(12-16) vs. 12(12-14) ng/mL), p<0.001]. Serum NAP1L1 levels were significantly higher in T4 stage tumors vs. T1, T2 and T3 stage tumors (p<0.001 for each), in T3 stage tumors vs. T1 and T2 stage tumors (p<0.001 for each) and in N2 stage tumors vs. N0 and N1 stage tumors (p<0.001 for each).
Our findings revealed for the first time the substantial rise in serum NAP1L1 levels among colon cancer patients as compared to controls and as correlated with the disease progression. Accordingly, NAP1L1 seems to be a potential biomarker for colon cancer, offering clinically important information on early diagnosis and risk stratification.
评估核小体组装蛋白 1 样 1（NAP1L1）在结肠癌患者中的诊断和预后价值。
本前瞻性多中心研究纳入了 95 例结肠癌患者（平均年龄（标准差）：61.0（1.7）岁，58.9%为男性）和 50 名健康个体（平均年龄（标准差）：61.0（2.3）岁，52.0%为男性）。记录对照组和结肠癌组患者的人口统计学数据（年龄、性别）和血清 NAP1L1 水平。在结肠癌患者中，进一步根据 TNM 分期和肿瘤大小分析血清 NAP1L1 水平。
与对照组相比，结肠癌患者的血清 NAP1L1 水平显著升高[中位数（最小-最大）：14（12-16）比 2（1-2）ng/mL，p<0.001]。在结肠癌患者中，肿瘤大小>4 cm 与<4 cm 相比[15（12-16）比 12（12-14）ng/mL，p<0.001]，M1 期与 M0 期相比[15（12-16）比 12（12-14）ng/mL，p<0.001]，血清 NAP1L1 水平均显著升高。T4 期肿瘤与 T1、T2 和 T3 期肿瘤相比（p<0.001 各期），T3 期肿瘤与 T1 和 T2 期肿瘤相比（p<0.001 各期），N2 期肿瘤与 N0 和 N1 期肿瘤相比（p<0.001 各期），血清 NAP1L1 水平均显著升高。
本研究首次发现结肠癌患者血清 NAP1L1 水平显著升高，并与疾病进展相关。因此，NAP1L1 似乎是结肠癌的一个潜在生物标志物，为早期诊断和风险分层提供了重要的临床信息。
